tiprankstipranks
Trending News
More News >
Metagenomi, Inc. (MGX)
NASDAQ:MGX
US Market
Advertisement

Metagenomi, Inc. (MGX) AI Stock Analysis

Compare
907 Followers

Top Page

MGX

Metagenomi, Inc.

(NASDAQ:MGX)

Rating:57Neutral
Price Target:
$2.50
▲(2.88%Upside)
The overall score reflects strong technical momentum and positive corporate events, offset by significant financial performance challenges and valuation concerns. The company's advancements in genome editing and robust cash reserves are positive, but profitability and cash flow issues must be addressed to enhance future stock performance.
Positive Factors
Collaborations and Funding
Metagenomi also leverages several collaborations with Ionis and Affini-T, which could be a good source of continued non-dilutive funds as development advances.
Product Validation
Updated data from the Hem A program demonstrate stable FVIII levels, suggesting a strong product profile and providing validation for the secreted protein platform.
Technology Advancements
MGX demonstrated advancements in technology with a system that allows large targeted genome integration in human cells.
Negative Factors
Financial Performance
MGX reported a net loss per share that was worse than the consensus estimate.
Financial Results
MGX reported a Q1 net loss of $25MM and had cash of $226MM.

Metagenomi, Inc. (MGX) vs. SPDR S&P 500 ETF (SPY)

Metagenomi, Inc. Business Overview & Revenue Model

Company DescriptionMetagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
How the Company Makes MoneyMetagenomi, Inc. generates revenue through the development and commercialization of its proprietary gene editing technologies. The company engages in strategic partnerships and collaborations with pharmaceutical and biotechnology companies to co-develop and license its technology for therapeutic applications. These partnerships often involve milestone payments, licensing fees, and royalties based on the successful development and commercialization of gene therapies. Additionally, Metagenomi may receive funding from research grants and government programs aimed at advancing genetic research and innovation.

Metagenomi, Inc. Financial Statement Overview

Summary
Metagenomi, Inc. exhibits strong revenue growth yet struggles with profitability and cash flow management. The balance sheet shows improving equity but requires careful monitoring of debt levels and liquidity. The company needs to address its operational and cash flow challenges to ensure long-term financial health.
Income Statement
52
Neutral
Metagenomi, Inc. has shown substantial revenue growth over the past years, with a remarkable increase from $243K in 2021 to $52.3M in 2024. However, the company is facing significant profitability challenges, as indicated by negative EBIT and net income margins, suggesting high operational costs or investments outpacing revenue growth. The gross profit margin improved significantly, but the net profit margin remains negative, indicating ongoing losses.
Balance Sheet
45
Neutral
The company's balance sheet shows a strong equity position with positive stockholders' equity in 2024, recovering from negative equity in previous years. The debt-to-equity ratio is relatively low, reflecting manageable leverage levels. However, the consistent negative equity in earlier years and the volatility in asset management could pose risks to financial stability.
Cash Flow
40
Negative
Metagenomi's cash flow statement highlights significant cash outflows, particularly in operating cash flow, which has been negative and worsening. The free cash flow is also negative, indicating potential liquidity challenges. Despite these concerns, the company has maintained substantial cash balances, possibly from financing activities, but sustainability may be an issue if cash burn continues.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue52.30M44.76M17.20M243.00K
Gross Profit52.30M-49.65M15.47M-144.00K
EBITDA-83.49M-74.28M-39.19M-20.75M
Net Income-78.06M-68.25M-43.59M-21.44M
Balance Sheet
Total Assets324.60M364.84M414.49M141.99M
Cash, Cash Equivalents and Short-Term Investments248.31M271.18M362.13M108.15M
Total Debt45.78M48.23M18.57M48.93M
Total Liabilities89.74M500.43M488.91M174.54M
Stockholders Equity234.86M-135.58M-74.43M-32.54M
Cash Flow
Free Cash Flow-112.19M-101.22M15.75M21.35M
Operating Cash Flow-109.07M-91.41M29.72M24.26M
Investing Cash Flow-88.16M45.73M-122.20M-74.32M
Financing Cash Flow84.01M1.01M239.59M39.92M

Metagenomi, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.43
Price Trends
50DMA
1.77
Positive
100DMA
1.70
Positive
200DMA
2.12
Positive
Market Momentum
MACD
0.20
Negative
RSI
66.94
Neutral
STOCH
82.02
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Positive. The current price of 2.43 is above the 20-day moving average (MA) of 2.02, above the 50-day MA of 1.77, and above the 200-day MA of 2.12, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 66.94 is Neutral, neither overbought nor oversold. The STOCH value of 82.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGX.

Metagenomi, Inc. Risk Analysis

Metagenomi, Inc. disclosed 77 risk factors in its most recent earnings report. Metagenomi, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We are currently, and may in the future be, subject to securities litigation, which is expensive and could divert management attention. This lawsuit, and potential similar or related lawsuits, could result in substantial damages, divert management's time and attention from our business, and have a material adverse effect on our financial position, results of operations or cash flows. Q4, 2024

Metagenomi, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (56)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$90.84M-31.93%-4.22%18.67%
56
Neutral
$6.23B21.98-28.61%4.90%10.73%-32.66%
$74.83M-92.68%
48
Neutral
$89.45M-273.36%883.05%62.93%
45
Neutral
$166.57M-22.38%
43
Neutral
$135.71M-138.78%32.77%
37
Underperform
$258.25M-141.69%-17.06%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MGX
Metagenomi, Inc.
2.43
-1.90
-43.88%
DOMH
Dominari Holdings
5.11
3.44
205.99%
ADAP
Adaptimmune Therapeutics
0.35
-1.02
-74.45%
IMAB
I-MAB
2.11
0.75
55.15%
INZY
Inozyme Pharma
4.00
-1.74
-30.31%
IOBT
IO Biotech
2.06
0.74
56.06%

Metagenomi, Inc. Corporate Events

Executive/Board ChangesShareholder Meetings
Metagenomi, Inc. Holds Annual Stockholders Meeting
Neutral
Jun 11, 2025

On June 10, 2025, Metagenomi, Inc. held its annual meeting of stockholders virtually, where a quorum was established with 18,765,221 shares present or represented by proxy. During the meeting, stockholders elected Willard H. Dere, M.D. as a Class I Director until 2028 and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Metagenomi Showcases Genome Editing Advances at ASGCT 2025
Positive
May 14, 2025

On May 14, 2025, Metagenomi, Inc. announced the presentation of three abstracts at the ASGCT 28th Annual Meeting, showcasing advancements in genome editing technologies. The data highlighted the potential of their compact nucleases for efficient gene editing and the CAST system for precise large gene integration, marking significant progress in developing in vivo precision medicines. These advancements could impact the treatment of neurological disorders and other diseases caused by loss-of-function mutations, enhancing Metagenomi’s position in the gene editing industry.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Metagenomi, Inc. Reports Q1 2025 Financial Results
Positive
May 13, 2025

Metagenomi, Inc. announced its first quarter 2025 financial results and business updates, highlighting a study on Hemophilia A that showed sustained factor VIII activity in nonhuman primates over 19 months, indicating potential for long-term therapeutic effects. The company is well-capitalized with $226 million in cash and securities, expected to support operations into 2027, and continues to advance its AI-driven metagenomics platform, with plans for further studies and technological enhancements.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025